DSM to Acquire Kensey Nash for $360 Million to Strengthen Biomedical Business

DSM says it will acquire Kensey Nash (Exton, PA), a technology-driven biomedical company, for about $360 million. DSM has entered into a definitive agreement with Kensey Nash, under which DSM would acquire all the outstanding shares of common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for $38.5/share in cash for a total enterprise value of about $360 million. The transaction has been approved by DSM’s supervisory board and by Kensey Nash’s board of directors. The agreed price represents a premium...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers